Clinical trial

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Study at a glance

Registry-backed

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: EARLY_PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov
StatusUNKNOWN
Study typeINTERVENTIONAL
Start date2020-03-25
PhaseEARLY_PHASE1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.